Heidelberg Pharma AG
XETRA:HPHA

Watchlist Manager
Heidelberg Pharma AG Logo
Heidelberg Pharma AG
XETRA:HPHA
Watchlist
Price: 2.64 EUR 0.76% Market Closed
Market Cap: 123m EUR

Wall Street
Price Targets

HPHA Price Targets Summary
Heidelberg Pharma AG

Wall Street analysts forecast HPHA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HPHA is 12.14 EUR with a low forecast of 12.02 EUR and a high forecast of 12.5 EUR.

Lowest
Price Target
12.02 EUR
355% Upside
Average
Price Target
12.14 EUR
360% Upside
Highest
Price Target
12.5 EUR
373% Upside
Heidelberg Pharma AG Competitors:
Price Targets
BMRN
Biomarin Pharmaceutical Inc
39% Upside
ALGS
Aligos Therapeutics Inc
540% Upside
2315
Biocytogen Pharmaceuticals Beijing Co Ltd
4% Downside
BINV
BioInvent International AB
158% Upside
IONS
Ionis Pharmaceuticals Inc
85% Upside
PYC
PYC Therapeutics Ltd
181% Upside
4597
Solasia Pharma KK
34% Upside
ALERS
Eurobio Scientific SA
21% Upside

Revenue
Forecast

Revenue Estimate
Heidelberg Pharma AG

For the last 7 years the compound annual growth rate for Heidelberg Pharma AG's revenue is 33%. The projected CAGR for the next 3 years is 14%.

33%
Past Growth
14%
Estimated Growth
Estimates Accuracy
-22%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Heidelberg Pharma AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

Net Income
Forecast

Net Income Estimate
Heidelberg Pharma AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HPHA's stock price target?
Price Target
12.14 EUR

According to Wall Street analysts, the average 1-year price target for HPHA is 12.14 EUR with a low forecast of 12.02 EUR and a high forecast of 12.5 EUR.

What is Heidelberg Pharma AG's Revenue forecast?
Projected CAGR
14%

For the last 7 years the compound annual growth rate for Heidelberg Pharma AG's revenue is 33%. The projected CAGR for the next 3 years is 14%.

Back to Top